Additionally, targeted therapy drugs such as bevacizumab (an anti-vascular endothelial growth factor (VEGF) antibody) and cetuximab (an anti-epidermal growth factor receptor (EGFR) antibody) are also used based on the CRC’s unique molecular characteristics [4,5]. This evidence concerns the gene VEGFA and colorectal carcinoma.